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Summary
CD14 is a well-known pattern-recognition receptor in
the innate immune system. Here, we show that CD14
enhances double-stranded RNA (dsRNA)-mediated
Toll-like receptor 3 (TLR3) activation. Bone marrow-
derived macrophages (BMDMs) from CD142/2 mice
exhibited impaired responses to polyinosine-polycyti-
dylic acid (pIpC) and reduced production of inflamma-
tory cytokines. CD142/2 mice injected with pIpC also
showed impaired cytokine production. When tested
with [32P] labeled pIpC small fragments (pIpCsf) that
maintain the inflammatory activity of crude pIpC, CD14
directly bound pIpCsf and mediated cellular uptake of
pIpCsf. Our data show that TLR3 is intracellular and
directly interacts with CD14. Internalized pIpCsf was
localized in the lysosomes via the endosomes. In un-
stimulated cells, neither CD14 nor TLR3 was detected
in the lysosomes. However, TLR3 was localized in the
lysosomes as was CD14 once the cells took up pIpC.
We also observed that internalized pIpCsf colocalized
with CD14 and TLR3. Consequently, CD14 mediates
pIpC uptake and enhances TLR3 signaling.
Introduction
The innate immune system functions as the first line of
defense against numerous pathogens. TLRs play an
essential role in the innate immune system, creating in-
nate immune signals that also activate adaptive immu-
nity (Beutler, 2004; Medzhitov and Janeway, 2000; Ule-
vitch, 2004). Since the first mammalian homolog of
Drosophila Toll was discovered (Medzhitov et al., 1997),
ten different human TLRs have been identified to date.
Except for TLR10, whose agonist is unknown, each
TLR has been shown to respond to distinct agonists, in-
cluding bacterial and fungal components as well as viral
RNA (Alexopoulou et al., 2001; Aliprantis et al., 1999;
Hayashi et al., 2001; Heil et al., 2004; Hemmi et al.,
2000; Poltorak et al., 1998; Underhill et al., 1999). dsRNA
is produced during viral replication by numerous viruses
and known to induce type I interferons (IFNa/b) in host
cells. A synthetic mimic of viral dsRNA, pIpC, has also
long been used to induce IFNa/b (Carter and De Clercq,
1974; Majde, 2001); however, the functional receptor for
dsRNA and pIpC was unknown for a long time. Recent
studies of TLR3 null mice indicate that dsRNA and
pIpC use TLR3 as their functional receptor because
these mice exhibit impaired responses to dsRNA and
pIpC (Alexopoulou et al., 2001). Not all TLRs function
*Correspondence: tobias@scripps.eduby themselves. For example, TLR4 requires MD2,
whereas TLR2 associates with TLR1 or TLR6. CD14
was originally identified as an LPS receptor, which is
attached to the cell surface by a glycosylphosphatidyli-
nositol (GPI) anchor (Wright et al., 1990). Later, it was
shown to function as an essential component of the
TLR4/MD2 complex in LPS signaling (Ulevitch, 2004).
CD14 also plays an essential role in cellular uptake of li-
gands, including LPS and phosphatidylinositol (Dunzen-
dorfer et al., 2004a; Wang and Munford, 1999), and inter-
acts with ligands, including bacterial and nonbacterial
products, to enhance ligand-mediated cell activation
(Dziarski et al., 2000).
In this study, we show that CD14 physically interacts
with pIpC and enables pIpC internalization. This CD14-
dependent pIpC uptake enhances intracellular TLR3 ac-
tivation, explaining why CD142/2 mice exhibited im-
paired responses to pIpC.
Results
CD14 Deficiency Impairs Responses to pIpC
in BMDMs
When BMDMs from CD142/2 mice were stimulated with
pIpC, we observed a decreased activation of NF-kB in
comparison with BMDMs derived from wild-type (wt)
mice (Figure 1A). As expected, the same observation
was made upon stimulation with LPS (Figure 1C), and
thus, we were concerned that the pIpC results could
be due to LPS contamination of the pIpC. However,
pIpC activation was seen in the presence of polymyxin
B (Figure 1A), an established inhibitor of LPS (Figure 1C).
As noted in the Experimental Procedures, assaying the
pIpC preparation for LPS with the Limulus amoebocyte
lysate assay revealed only a very low level of LPS con-
tamination. Furthermore, TLR4 deficiency had no effect
on NF-kB activation in response to pIpC (compare Fig-
ures 1B and 1A), although it did have the expected inhib-
itory effect on NF-kB activation in response to LPS
(compare Figures 1D and 1C). Additionally, MyD88 defi-
ciency delayed NF-kB activation in response to LPS
(compare Figures 1D and 1C) but had no effect on the
time course of NF-kB activation initiated with pIpC
(compare Figures 1B and 1A). However, the effects of
MyD88 and TLR4 deficiency on NF-kB activation were
as expected also with CpG and MALP-2. Thus, we con-
clude that the effect of CD14 deficiency on pIpC activa-
tion is not due to LPS contamination of the pIpC.
CD14 deficiency differentially impaired cytokine re-
sponses to pIpC and LPS in addition to differentially im-
pairing NF-kB activation by these agonists. Figures 1E
and 1F show that CD14 deficiency eliminated IL-12p40
expression in response to LPS, whereas CD14 defi-
ciency roughly halved IL-12p40 expression in response
to pIpC. TLR3 deficiency had the expected dramatic
and minimal effects on IL-12p40 expression in response
to pIpC and LPS, respectively. The effects of CD14 or
TLR3 deficiency on IL-6 expression were similar to those
on IL-12p40 expression (Figures 1G and 1H).
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154Figure 1. Impaired Responses to pIpC in
CD14-Deficient Macrophages
(A–D) Bone marrow-derived macrophages
(BMDMs) from wild-type (wt) and CD142/2
mice (A and C) as well as MyD882/2 and
TLR42/2 mice (B and D) were stimulated with
pIpC (20 mg/ml), LPS (0.2 mg/ml), MALP-2
(10 ng/ml), or CpG (10 mg/ml) in the presence
or absence of 50 mg/ml polymyxin B (PB). The
nuclear translocation of NF-kB was deter-
mined by EMSA at the indicated time points.
Abbreviation: NS, nonspecific bands.
(E–H) BMDMs were stimulated with LPS
(0.2 mg/ml) (E and G) and pIpC (20 mg/ml)
(F and H). At the indicated time points,
IL-12p40 (E and F) and IL-6 (G and H) in
the culture supernatants were measured by
ELISA. Data are shown as mean6 SD of three
different experiments. *p < 0.05 versus wt
at the corresponding time points (Mann-
Whitney U test).In vivo, the effect of CD14 deficiency was similar to
that seen with BMDM in vitro. As shown in Figures 2A
and 2B, at 2 or 6 hr after intraperitoneally (ip) administra-
tion of pIpC, CD142/2 mice had significantly decreased
plasma IL-12p40 in comparison to wt mice at lower
doses of pIpC. TLR32/2 mice had no detectable re-
sponse to 10 or 25 mg pIpC and a weak response to 50
mg pIpC (Figures 2A and 2B).
CD14-enhanced TLR3 activation was further exam-
ined by luciferase reporter assay linked to ISRE or
IFN-b promoter activation. HEK293 cells were tran-
siently cotransfected with TLR3 plasmid and increasing
amounts of CD14 plasmid. When stimulated with pIpC,
CD14 significantly enhanced TLR3 activation, which
subsequently mediates ISRE and IFN-b promoter activ-
ities (Figures 2C and 2D). Furthermore, soluble CD14 re-
stored pIpC-mediated NF-kB activities when sCD14
was added to CD14-deficient BMDMs upon pIpC stimu-
lation (Figure 2E). On the other hand, CD14-deficient
BMDMs also showed decreased STAT1 phosphor-
ylation upon stimulation with pIpC as well as LPS
(Figure 2F).Thus, whether one looks in vitro or in vivo, with pri-
mary cells or transfected cells, CD14 expression en-
hances TLR3 mediated responses to pIpC.
CD14-Dependent pIpCsf Uptake
To further investigate how CD14 enhances TLR3 activa-
tion in response to pIpC, we made short fragments of
pIpC (pIpCsf),w200 bp, which could be utilized for cel-
lular uptake and localization studies. This was done by
RNase III treatment and gel filtration purification with Se-
phadex G-75 (Figure 3A). The purified pIpCsf maintained
the inflammatory activity of crude pIpC as confirmed by
NF-kB nuclear translocation assays (Figures 3B and 3C).
BMDMs from wt mice, but not TLR32/2 mice, were acti-
vated by pIpCsf and crude pIpC, whereas LPS activated
both BMDMs (Figure 3B).
We utilized confocal microscopy to study nuclear
translocation of the NF-kB p65 subunit. In Chinese ham-
ster ovary (CHO) cells stably transfected with various
combinations of CD14, TLR3, and TLR4 (Figure 3C),
Alexa Fluor 488-labeled pIpCsf (AF488-pIpCsf) as well
as crude pIpC activated CHO/CD14/TLR3 and partially
CD14 Enhances TLR3 Activation
155Figure 2. pIpC-Induced IL-12p40 Production Is Decreased in CD142/2 Mice, and CD14 Enhances pIpC-Mediated TLR3 Activation
(A and B) Wt, CD142/2, and TLR32/2mice were injected intraperitoneally (ip) with 10, 25, and 50 mg pIpC. Sera were taken 2 hr (A) and 6 hr (B) later,
and serum levels of IL-12p40 were measured by ELISA. Results are shown as the mean6SD of sera samples from three mice. *p < 0.05 versus wt
at the corresponding time points (Mann-Whitney U test). Abbreviation: C, saline control.
(C and D) CD14-dependent enhancement of pIpC-mediated ISRE and IFN-b promoter activities in HEK293. Cells were transiently transfected
with control vector (0.1 mg/ml), mCD14 plasmid (0.1 mg/ml), TLR3 plasmid (0.1 mg/ml), or TLR3 plasmid plus increasing amounts (0.01, 0.05,
0.1, 0.25, and 0.5 mg/ml) of mCD14 plasmid. Each sample was cotransfected with pSV-b-galactosidase vector plus pISRE-Luc plasmid (C) or
p125-Luc plasmid (D) (0.075 mg/ml each). After 24 hr, cells were stimulated with pIpC (20 mg/ml) or LPS (0.2 mg/ml) for 6 hr. Thereafter, cells
were lysed and the luciferase activity was measured. All the luciferase activity was normalized with b-galactosidase activity. Data are shown
as mean 6 SD of three different experiments. *p < 0.05 versus TLR3 alone (Mann-Whitney U test).
(E) Soluble CD14 rescues the defect of TLR3 activity in CD14-deficient macrophages. BMDMs from wt and CD142/2 mice were stimulated with
pIpC (10 mg/ml) plus polymyxin B (PB, 50 mg/ml) in the presence of increasing amounts of sCD14 (lane 1, none; lane 2, 0.05 mg/ml; lane 3, 0.5 mg/ml;
and lane 4, 5.0 mg/ml) for 1 hr. The nuclear translocation of NF-kB was determined by EMSA. Abbreviations: C, control; NS, nonspecific bands.
(F) pIpC-induced STAT1 phosphorylation is decreased in CD14-deficient macrophages. BMDMs from wt or CD142/2 mice were stimulated with
pIpC (20 mg/ml), LPS (0.2 mg/ml), or IFN-g (100 U/ml) for different time periods as indicated. Phosphorylated STAT1 (p-STAT1) and residual STAT1
were determined by Western blotting using anti-p-STAT1 or anti-STAT1 antibody.activated CHO/TLR3 cells but did not activate CHO/
CD14 or CHO/CD14/TLR4 cells. LPS activated only cells
expressing CD14, whereas TNFa activated all four cell
lines (Figure 3C). Thus, both pIpCsf and AF488-pIpCsf
have the activity of crude pIpC in these assays.
pIpCsf was labeled with [g-32P]ATP, and the [32P]-
pIpCsf was used for uptake experiments with various
stably transfected CHO cell lines. [32P]-pIpCsf was read-
ily detected to be internalized in CHO cells. However,
this internalization predominantly occurred in CHO cellsexpressing CD14, indicating that pIpCsf uptake occurs
in a CD14-dependent manner (Figure 4A). Interestingly,
pIpCsf uptake was completely TLR3 independent.
Some CD14-independent uptake of [32P]-pIpCsf was
observed in CHO/TLR3 as well as CHO/Vector cells
when incubated over 4 hr (Figure 4A). The CD14-depen-
dent pIpCsf uptake pattern was also observed when
AF488-pIpCsf was used with the same CHO stable cell
lines, which was determined by microscopy (data not
shown). We further tested whether soluble CD14 can
Immunity
156Figure 3. Purified pIpCsf Mediates TLR3-Dependent Cell Activation
(A) Production of homogeneous 200 bp-short pIpCsf. Crude pIpC was partially digested with RNase III and fractionated into discrete size poly-
mers and purified by gel filtration using Sephadex G-75. Crude pIpC and pIpCsf (1 mg each) were run on a 1% agarose gel.
(B) pIpCsf activity. BMDMs from wt or TLR32/2 mice were stimulated with pIpC (20 mg/ml), pIpCsf (20 mg/ml), or LPS (0.2 mg/ml) for 1 hr. The
nuclear translocation of NF-kB was determined by EMSA. Abbreviation: NS, nonspecific bands.
(C) pIpCsf-induced nuclear translocation of NF-kB p65 subunit. CHO stable cell lines, CHO/CD14, CHO/CD14/TLR4, CHO/CD14/TLR3, and CHO/
TLR3 were stimulated with pIpC (20 mg/ml), AF488-labeled-pIpCsf (20 mg/ml), LPS (0.2 mg/ml), or TNFa (0.05 mg/ml) for 2 hr, stained for NF-kB p65
subunit (red), and analyzed by fluorescence microscopy (green, intracellular AF488-pIpCsf; blue, DAPI nuclear stain). The arrows indicate inter-
nalized AF488-pIpCsf. The bar represents 10 mm.enhance the small portion of uptake observed in CHO/
Vector and CHO/TLR3 also (Figure 4A). When CHO cells
were incubated with a complex of [32P]-pIpCsf and
sCD14, the pIpCsf uptake was enhanced by sCD14
compared to CHO cells incubated with [32P]-pIpCsf
alone (Figure 4B). sCD14 also enhanced [32P]-pIpCsf
uptake in CHO/CD14 cells (data not shown).
To investigate whether CD14-dependent pIpCsf up-
take could involve direct binding of pIpCsf to CD14,
we next performed ligand binding assays with purified
soluble CD14. When [32P]-pIpCsf was reacted with dif-
ferent concentrations of sCD14, pIpCsf specifically in-teracted with sCD14 in a dose-dependent manner (Fig-
ure 4C). Moreover, this binding was abolished when
unlabeled pIpCsf was added to the reactions (Figure 4D).
pIpCsf binding to CD14 was also abolished by various
RNA derivatives, including pApU, pU, and pC, whereas
a DNA derivative, pdIpdC, only weakly inhibited the
binding (Figure 4D). Binding of pIpCsf to CD14 was fur-
ther confirmed by using anti-CD14 (mouse monoclonal
antibody 63D3), which led to a super shift of the [32P]-
pIpCsf/CD14 complex (Figure 4E). These data provide
evidence that pIpCsf and other RNAs bind directly to
CD14.
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157Figure 4. pIpCsf Uptake Is Dependent upon CD14, and pIpCsf Directly Binds to CD14
(A) Various CHO stable cell lines were incubated with 0.1 mg/ml [32P]-pIpCsf for various time intervals in serum-free RPMI. The cells were washed
three times with PBS and treated with 20 mg/ml proteinase K for 1 hr at 37ºC to remove cell surface proteins/receptors. The cells were than har-
vested, washed three times with PBS, and lysed in 200 ml of 2% SDS and 50 mM EDTA, pH 7.4. The lysates were assayed in scintillation fluid for
radioactivity. Data are shown as mean 6 SD of three different experiments.
(B) Soluble CD14-enhanced pIpCsf uptake. CHO cells were incubated with 0.1 mg/ml [32P]-pIpCsf or 0.1 mg/ml [32P]-pIpCsf/sCD14 (20 mg/ml)
complex for various time intervals in serum-free RPMI. [32P]-pIpCsf and sCD14 were preincubated to form a complex for 30 min at 37ºC. Other
procedures were as described in (A).
(C–E) Ligand binding was performed with [32P]-pIpCsf and purified soluble CD14. [32P]-pIpCsf (10 ng/reaction of 20 ml) was mixed with increasing
concentrations of sCD14 protein (0.05, 0.5, 1.0, and 2.0 mM) (C) or in the presence of various cold competitors (53 and 503, each) as noted (D).
The reactions were incubated at room temperature for 30 min and run on a 4% native acrylamide gel followed by autoradiography. Anti-CD14
antibody (63D3) (5 mg/ml) was added to the reaction 10 min before termination (E).Subcellular Association of pIpCsf with TLR3
and CD14
When we assessed the cellular location of TLR3 by
FACS analysis, we only detected TLR3 in permeabilized
cells (Figure 5A). This confirms that TLR3 is intracellu-
larly localized, as previously shown by others (Matsu-
moto et al., 2003). Similarly, confocal microscopic ob-servation of CHO/CD14/TLR3 cells revealed that TLR3
is intracellular (Figure 5B). In contrast, CD14 was ex-
pressed on the cell surface as well as in the cytoplasm
(Figures 5A and 5B). Interestingly, subcellular TLR3 and
CD14 were colocalized independently of pIpC (Fig-
ure 5C, panels 1 and 2); in these images, 93% and
95% of the TLR3 colocalized with CD14 in the absence
Immunity
158Figure 5. Intracellular TLR3 Colocalizes and Coimmunoprecipitates with CD14
(A) Intact or permeabilized CHO/CD14/TLR3 cells were stained with anti-TLR3 or anti-CD14 antibody (bold line) and analyzed by FACS; dotted
line indicates a control IgG staining.
(B and C) CHO/CD14/TLR3 cells were fixed, permeabilized, and stained for TLR3 or CD14 (green) (B) or both (red or green as noted) (C). pIpC
(20 mg/ml) was added to the cells 2 hr before fixation (C2). F-actin was stained with fluorescent phallotoxin (red) (B) and nuclei with DAPI
(blue) (B and C). Similarly, CHO/TLR3/TLR9 and CHO/CD14/TLR9 cells were fixed, permeabilized, and stained for TLR9 (red), TLR3 (green),
and CD14 (green) (C3 and C4). Images were acquired by deconvolution confocal microscopy. The colocalization coefficient for red against green
was 0.931 (C1), 0.953 (C2), 0.361 (C3), and 0.162 (C4) analyzed by NIH image analysis software packages, Image J (v. 1.33). The bars represent
10 mm.
(D) HEK293 cells were transiently cotransfected with CD14 and TLR3 plasmids (0.5 mg/ml each). After 48 hr, cells were lysed and immunopre-
cipitated with anti-Myc antibody. pIpC (20 mg/ml) was added to the cells 6 hr before lysis. Western blotting was done with anti-Myc or anti-
TLR3 antibody as noted. Abbreviations: IP, immunoprecipitation; WB, Western blotting.
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159Figure 6. TLR3 and CD14 Colocalize with Internalized AF488-pIpCsf, and pIpCsf Locates to the Lysosomes via the Endosomes
(A) Internalized AF488-pIpCsf colocalizes with TLR3 and CD14. CHO/CD14/TLR3 cells were incubated with AF488-pIpCsf (20 mg/ml) in serum-
free RPMI for 2 hr. Cells were washed with PBS, fixed/permeabilized, and stained for TLR3 or CD14 (red) followed by DAPI nuclear staining (blue).
Images were acquired by deconvolution confocal microscopy. The colocalization coefficient for green against red was 0.82 (A1) and 0.712 (A2),
as analyzed by NIH image analysis software packages, Image J (v. 1.33). The bars represent 10 mm.
(B) TLR3 activation by pIpC requires endosomal maturation. Mouse BMDMs were preincubated with or without 5 mM chloroquine for 30 min and
stimulated with pIpC (10 mg/ml), CpG DNA (10 mg/ml), or LPS (0.2 mg/ml) for 1 hr. The nuclear translocation of NF-kB was determined by EMSA.
Abbreviations: C, control; Chlrq, chloroquine; and NS, nonspecific bands.
(C) AF488-pIpCsf locates to the lysosomes via the endosomes. CHO/CD14/TLR3 cells were incubated with AF488-pIpCsf (20 mg/ml) in serum-
free RPMI for 2 hr. Cells were either further incubated with 50 mM LysoTracker reagent (red) for 1 hr or fixed/permeabilized to be stained for EEA1
or LAMP-1 (red). Nuclei were stained with DAPI (blue). The colocalization coefficient for green against red was 0.52 (C1), 0.869 (C2), and 0.62 (C3),
as analyzed by NIH image analysis software packages, Image J (v. 1.33). The bars represent 10 mm.or presence of pIpC, respectively. Moreover, TLR3 was
also coimmunoprecipitated with CD14 independently
of pIpC (Figure 5D). These figures also show that there
is more CD14 than TLR3. When TLR9, a known intracel-
lular TLR (Latz et al., 2004), was observed together with
CD14 or TLR3, TLR9 only partially colocalized with CD14
and only minimally with TLR3 (Figure 5C, panels 3 and 4);
in these images 36% and 16% of the TLR9 colocalizedwith CD14 and TLR3, respectively. This implies that sub-
cellular TLR3 and TLR9 are localized differently from
each other.
When AF488-pIpCsf was internalized in CHO/CD14/
TLR3 cells, it was 82% colocalized with TLR3 and 71%
colocalized with CD14, as determined by confocal mi-
croscopy (Figure 6A, panels 1 and 2, respectively), im-
plying that AF488-pIpCsf is directly associated with
Immunity
160Figure 7. pIpC-Dependent Lysosomal Localization of TLR3 and CD14
CHO/CD14/TLR3 cells were incubated with or without pIpC (20 mg/ml) for 2 hr. Cells were washed with PBS, fixed/permeabilized, and double
stained for TLR3 or CD14 (green) plus LAMP-1 (red) as noted. Nuclei were stained with DAPI (blue). The colocalization coefficient for red against
green was 0.12 (1), 0.72 (2), 0.211 (3), and 0.61 (4), as analyzed by NIH image analysis software packages, Image J (v. 1.33). The bars represent
10 mm.TLR3 and CD14 during cell activation. These data sug-
gest that TLR3 and CD14 constitutively interact with
each other, and by virtue of this interaction, CD14 brings
pIpCsf to TLR3.
Subcellular Localization
We initially pursued subcellular localization of TLR3 and
CD14 by coimmunostaining with different organelle res-
ident proteins. Because subcellular TLR9 was known to
be localized in the endoplasmic reticulum (ER) (Latz
et al., 2004; Leifer et al., 2004), in our study, we initially
sought colocalization of TLR3 and CD14 with the ER-
marker protein calnexin. We observed that 32% and
31% of TLR3 and CD14 were colocalized with calnexin,
respectively (data not shown). We also observed that
47% and 42% of TLR3 and CD14, respectively, were lo-
calized in the Golgi apparatus as determined by coun-
terstaining for the Golgi 58K protein (p58K) (data not
shown). These data indicate that, unlike TLR9, TLR3 is
distributed in multiple intracellular compartments.
As with TLR9 activation by CpG (Ha¨cker et al., 1998;
Rutz et al., 2004), TLR3 activation by pIpC was sensitive
to chloroquine inhibition in mouse BMDM cells, implying
that pIpC-induced TLR3 activation may require endoso-
mal maturation (Figure 6B). Indeed, AF488-pIpCsf was
localized in the endosomal compartments as deter-
mined by counterstaining with early endosome antigen
1 (EEA1) (Figure 6C, panel 1). The internalized AF488-
pIpCsf was also detected to reside in the lysosomal
compartments. This was determined by colocalization
of AF488-pIpCsf with LysoTracker probes (Figure 6C,
panel 2) and confirmed by colocalization with lyso-some-associated membrane protein 1 (LAMP-1) (Fig-
ure 6C, panel 3). Neither TLR3 nor CD14 was located in
the lysosomes of unstimulated CHO/CD14/TLR3 cells;
however, both proteins were detected in the lysosome
when the cells were stimulated with pIpC, as determined
by colocalization with LAMP-1 (Figure 7).
We also attempted sucrose density gradient fraction-
ation to separate the microsomes purified from CHO/
CD14/TLR3 cells before and after pIpC treatment.
When cells were treated with pIpC, both TLR3 and
CD14 showed a slight shift toward light vesicle fractions
where the lysosomes and endosomes were detected
(data not shown).
Discussion
The results presented here demonstrate that CD14 sig-
nificantly enhances pIpC-mediated TLR3 activation by
aiding cellular uptake of pIpC, so that CD142/2 mice ex-
hibit impaired responses to pIpC and reduced produc-
tion of inflammatory cytokines. Our study also suggests
that CD14-mediated internalization of pIpC follows a
standard endosomal pathway; that is, endosomal up-
take of CD14-pIpC complexes is followed by acidifica-
tion-dependent fusion with lysosomes (Luzio et al.,
2001). Once the CD14-pIpC complexes are lysosomal,
TLR3 detects the presence of pIpC and activates signal-
ing to yield cell activation. That pIpC follows this path-
way has previously been suggested by others (Matsu-
moto et al., 2003); our results show that CD14
enhances the process and that pIpC stimulates lyso-
somal association of TLR3 and CD14.
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161CD14 has not previously been shown to enhance
TLR3 dependent phenomena or to associate with
dsRNA or pIpC. However, it is well known to associate
with a variety of other microbially derived molecules,
prototypically with LPS but also with a variety of other
lipids as well as peptidoglycan and mannans (Dziarski
et al., 1998; Hailman et al., 1994; Kirkland et al., 1993; Pu-
gin et al., 1994; Tobias et al., 1993; Tobias et al., 1995;
Vasselon et al., 2004; Wang et al., 1998; Wright et al.,
1990). Our data seem quite strong: the in vivo studies us-
ing CD142/2 mice demonstrate that these mice show
significantly impaired inflammatory cytokine production
when injected with pIpC (Figures 2A and 2B). The elec-
trophoretic mobility shift data show clearly that CD14
associates with [32P]-pIpCsf and enables cellular uptake
(Figure 4). Furthermore, complexes of CD14 with AF488-
pIpCsf are observed internally (Figure 6A, panel 2). Be-
fore exposure to pIpC, CD14 and TLR3 can be associ-
ated with each other (Figure 5C). After cells are exposed
to AF488-pIpCsf, the AF488-pIpCsf is seen associated
with endosomes and lysosomes (Figure 6C), where
CD14 and TLR3 are then also seen (Figure 7). A similar
endocytic pathway was previously shown for TLR9 acti-
vation by CpG DNA, which requires endosomal acidifi-
cation (Ha¨cker et al., 1998; Rutz et al., 2004). Latz et al.
recently showed that CpG DNA was transported to the
lysosomal compartments via early endosomes and as-
sociated with TLR9 recruited from the ER (Latz et al.,
2004). In our study, we saw partial localization of TLR3
and CD14 in the ER as well as in the Golgi. Matsumoto
et al. showed that Ba/F3 cells stably expressing TLR3
present TLR3 in multivesicular bodies that are late endo-
somal compartments involved in the endocytic traffick-
ing pathways (Matsumoto et al., 2003). Indeed, our data
showed that pIpC is taken up into the endosomal com-
partments and subsequently transported to the lyso-
somal compartments. Moreover, this event is essential
for the lysosomal localization of TLR3, indicating that
TLR3 is recruited to the lysosomes upon internalization
of pIpC (Figures 6C and 7).
As the data of Figures 2C and 2D show, there is some
activation independent of membrane bound CD14
(mCD14). Presumably, this is due to the mCD14-inde-
pendent uptake shown in Figure 4A. We were not able
to visualize this uptake by fluorescence microscopy to
know whether it follows the same pathway that the
CD14-mediated uptake follows. However, it may sug-
gest that the primary function of CD14 is to enhance
pIpC uptake rather than to present pIpC to TLR3. The
mechanism by which mCD14 enhances uptake of pIpC
is unknown. However, it does not require that CD14 be
membrane bound inasmuch as soluble CD14 enhanced
pIpC uptake (Figure 4B) and enhanced activation (Fig-
ure 2E). This function of CD14 is not unique to pIpC.
We have previously shown that mCD14, but not TLR4,
is required for LPS uptake, that sCD14 also enables up-
take of LPS, and that sCD14 is internalized with LPS
(Dunzendorfer et al., 2004a; Gegner et al., 1995; Tapping
and Tobias, 1997).
Recently, a three-dimensional structure for CD14 has
been reported, indicating that there is a large hydropho-
bic pocket on the NH2-terminal side of the horseshoe-
like structure in which the LPS binding region is located
(Kim et al., 2005). We have tested a variety of CD14-specific monoclonal antibodies known to inhibit LPS-
dependent cellular activation, such as 28C5, 18E12,
and MY4 (Kirkland et al., 1993); none of these had any
inhibitory activity against pIpC (data not shown). This
is not surprising because RNA and pIpC are hydrophilic
molecules, so that the hydrophobic NH2-terminal pocket
of CD14 may not be relevant to their binding. Although
both ss and dsRNAs bind to CD14, only dsRNA activates
TLR3. This suggests that the specificity of activation re-
sides with TLR3 rather than CD14.
Experimental Procedures
Reagents and Antibodies
pIpC, polycytidylic acid (pC), polyuridylic acid (pU), and Poly(dI-dC)-
Poly(dI-dC) were purchased from Amersham Biosciences (Piscat-
away, NJ). Possible contamination with bacterial endotoxin in
pIpC was determined by a Limulus amebocyte lysate assay (Bio-
Whittaker, Walkersville, MD). We found less than 0.005 units (EU)
per mg pIpC. Polyadenylic acid-polyuridylic acid (pApU) was pur-
chased from Sigma-Aldrich (St. Louis, MO). Lipopolysaccharide
(LPS) from Escherichia coli (O111:B4) was purchased from List Bio-
logical Laboratories (Campbell, CA) and repurified as previously de-
scribed (Lee et al., 2002). The antibodies used in the experiments
were anti-p58K from Sigma-Aldrich, anti-Myc from Covance-Berke-
ley Antibody Company (Richmond, CA), anti-pSTAT1 from Zymed
(San Francisco, CA), anti-TLR9 (14-9099) from eBioscience (San
Diego, CA), anti-TLR3 (sc-16238) and anti-p65 (sc-109) from Santa
Cruz Biotechnology (Santa Cruz, CA), and anti-Calnexin from Stress-
gen (Victoria, BC, Canada). Additionally, anti-CD107a (LAMP-1),
anti-EEA1, and anti-CD14 (clone: 55-3) were purchased from BD
Biosciences PharMingen (San Diego, CA), whereas anti-CD14 anti-
body (mAb 63D3) was produced in our laboratory (the original clone
was kindly provided by R.W. Johnson Pharmaceutical Research
Institute, La Jolla, CA). All secondary antibodies used in fluores-
cence microscopy were Alexa Fluor conjugates (Molecular Probe,
Eugene, OR). Mouse IL-12p40 and IL-16 ELISA kits were purchased
from BD Biosciences.
Cell Culture
HEK293 cells were grown in DMEM (Invitrogen, Carlsbad, CA) with
10% fetal calf serum (FCS). All CHO stable cell lines were grown in
RPMI (Invitrogen) with 10% FCS. CHO/RSV and CHO/hCD14 cells
were selected and maintained with 0.2 mg/ml G418 as described
(Gegner et al., 1995). CHO-K1 or CHO/hCD14 cells were transfected
with pEF6/V5-His-TOPO/hTLR3 to produce CHO/hTLR3 or CHO/
hCD14-hTLR3 stable cell lines. Similarly, pEF6/V5-His-TOPO/
hTLR9 was used to produce CHO/hTLR3-hTLR9 stable line. The
lines were selected and maintained with 10 mg/ml Blastacidin (Invi-
trogen).
Mouse Study and Preparation of BMDMs
CD142/2 mice were obtained from The Jackson Laboratory (Bar
Harbor, ME). MyD882/2 and TLR42/2 mice were obtained from Dr.
S. Akira (Osaka University, Osaka, Japan). TLR32/2 mice were ob-
tained from Dr. R.A. Flavell (Yale University School of Medicine,
New Haven, CT). Mice (6- to 10-weeks-old) were injected ip with
10, 25, or 50 mg of pIpC. Sera were taken 2 and 6 hr later, and serum
levels of IL-12p40 were measured by ELISA. Macrophages derived
from mouse bone marrow cultures were obtained according to the
procedures modified from Celada et al. (1984). Briefly, mice were
killed by halothane inhalation, and both femurs were dissected
free of adherent tissue. The marrow cells were eluted by irrigation
of inner bone with BMDM media (70% DMEM containing 10%
FCS, 2 mM L glutamine, and 1 mM sodium pyruvate plus 30% L
cell cofactor). Cells were washed by centrifugation and plated in
10 mm culture dishes with BMDM media. After 7 days, macrophages
were harvested with PBS-based cell dissociation buffer (Invitrogen)
and used for experiments. For measurement of cytokine production
in BMDMs, macrophages (1 3 106 cells/well) were cultured in a 12-
well plate and stimulated as indicated in the figures. IL-12p40 and
IL-6 in the cultured supernatants were measured by ELISA.
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BMDM cells were grown in 12-well tissue culture plates with BMDM
media for 24 hr and then stimulated with pIpC (20 mg/ml), LPS (0.2
mg/ml), MALP-2 (10 ng/ml), or CpG (10 mg/ml) at the different time
points as indicated in the figure legends. Cells were lysed with buffer
A (10 mM HEPES [pH 7.9], 10 mM KCL, 0.1 mM EDTA, 0.1 mM EGTA,
1 mM DTT, and 1% Nonidet P40) followed by centrifugation. The pel-
let was treated with buffer B (20 mM HEPES [pH 7.9], 0.4 M NaCl,
1 mM EDTA, 1 mM EGTA, and 0.1 mM PMSF) to prepare nuclear ex-
tracts. EMSA was performed utilizing NF-kB oligonucleotide probe
(Promega, Medison, WI) labeled with [g-32P]ATP (Amersham Biosci-
ences) using T4 polynucleotide kinase (New England BioLabs) as
previously described (Lee et al., 2002).
Luciferase Reporter Assay
Luciferase gene reporter assay was performed with p125-Luc (IFN-
b promoter) plasmid (a gift from Dr. Taniguchi, Univ. of Tokyo) and
pISRE-Luc plasmid (Stratagene, La Jolla, CA). HEK293 cells were
grown in 12-well plates with DMEM/10% FCS. On the following
day, cells were transiently transfected with TLR3 plasmid (0.1 mg/
ml) alone or with an increasing amount of CD14 plasmid. Cells
were also cotransfected with 0.05 mg/ml either p125-Luc or pISRE-
Luc plasmid, and pSV-b-galactosidase vector (Promega, Madison,
WI). After 24 hr, cells were stimulated with pIpC or LPS for 6 hr,
and thereafter, cell extracts were prepared. The luciferase activity
was measured by a Luciferase Reporter Assay System (Promega),
and b-galactosidase activity was measured with O-nitrophenyl-
b-D-galactopyranoside as substrate. Luciferase activity reported in
the figures is normalized for transfection efficiency with the b-galac-
tosidase activity.
STAT1 Phosphorylation Assay
BMDM cells were grown in 12-well tissue culture plates with BMDM
media for 24 hr and stimulated with pIpC (20 mg/ml), LPS (0.2 mg/ml),
or IFN-g (100 U/ml) at the different time points as indicated in the fig-
ure legends. Cells were lysed with lysis buffer (150 mM NaCl, 1%
Nonidet P40, 5 mM EDTA, 50 mM Tris-HCl, pH 7.5) containing prote-
ase inhibitor cocktails (Roche). The supernatants were separated on
a 4%–12% Bis-Tris NuPAGE gel (Invitrogen) and transferred to nitro-
cellulose membrane. Western blotting was performed by probing
the membrane with either anti-phospho-STAT1 or anti-STAT1 anti-
body according to standard protocols.
pIpCsf Preparation and Labeling
Crude pIpC was partially digested with ShortCut RNase III (New
England BioLabs), and the digested pIpC was fractionated into dis-
crete size polymers by gel filtration chromatography using Sepha-
dex G-75 (Sigma). The fractions were analyzed by agarose gel elec-
trophoresis. A fraction consisting of 200 bp short, homogeneous
fragments (pIpCsf) was then extracted by phenol/chloroform and
eluted by ethanol precipitation. For uptake experiments, pIpCsf
was further dephosphorylated by calf intestinal phosphatase (New
England BioLabs) and labeled with [g-32P]ATP using T4 polynucleo-
tide kinase (New England BioLabs). For fluorescence microscopy,
pIpCsf was labeled with AF488 reagents according to the manufac-
turer’s instructions (Molecular Probe).
Ligand Binding Assay
Ligand binding was performed with [32P]-pIpCsf and purified soluble
CD14. sCD14 was expressed by the baculovirus expression system
and purified in our laboratory as previously described (Tapping and
Tobias, 1997). [32P]-pIpCsf (10 ng/reaction) was mixed in binding
buffer (20 mM Tris-HCl [pH 7.5], 200 mM KCl, 10 mM MgCl2, 10%
glycerol, 0.2 mM DTT, 0.1% bovine serum albumin, and 0.2 mM
spermidine) with various concentrations of sCD14 protein as indi-
cated in the figure legends, or in the presence of various cold com-
petitors, including pIpCsf, pApU, pU, pC, and pdIpdC (53 and
503, each). The reactions were incubated at room temperature
for 30 min and analyzed on a 4% native acrylamide gel followed
by autoradiography.
pIpCsf Uptake
CHO stable cell lines (CHO/Vector, CHO/CD14, CHO/TLR3, and
CHO/CD14/TLR3) were grown in 12-well tissue culture plates withRPMI/10% FCS for 24 hr. The cells were then washed three times
with serum-free RPMI and incubated with 32P-pIpCsf (0.1 mg/ml) in
serum-free RPMI for various time intervals. The cells were washed
three times with PBS and treated with 250 mg/ml proteinase K (EMD
Biosciences, San Diego, CA) in PBS for 1 hr at 37ºC to remove cell
surface proteins/receptors. The 32P counts remaining after protein-
ase K treatment were considered to be intracellular (Dunzendorfer
et al., 2004b). The cells were then harvested, washed three times
with PBS, and lysed in 200 ml of 2% SDS and 50 mM EDTA (pH 7.4).
The lysates were assayed in scintillation fluid for radioactivity.
Immunofluorescence Microscopy
Various CHO stable cell lines were grown in 8-well Nunc Lab-Tec II
chambered coverglasses (Nalge Nunc, Naperville, IL) with RPMI/
10% FCS for 24 hr. After incubation with or without AF488-pIpCsf
(10 mg/ml) for 2 hr, cells were fixed and permeabilized with a
Cytofix/Cytoperm kit according to the manufacturer’s instructions
(BD Biosciences PharMingen). Cells were blocked with 10% normal
host serum of secondary antibody for 30 min at room temperature
and then incubated with 10 mg/ml of primary antibodies for 1 hr at
room temperature. Cells were washed three times and further incu-
bated with 2.5 mg/ml of Alexa Fluor-conjugated secondary anti-
bodies plus 0.5 mM DAPI for 1 hr at room temperature. Additionally,
in some cases, F-actin was stained with Alexa Fluor 660 phalloidin
(Molecular Probe). After incubation, cells were washed and covered
with SlowFade Light Antifade reagent (Molecular Probes). Thereaf-
ter, deconvolution microscopy of the prepared samples was per-
formed with a Delta Vision Optical Sectioning Microscope (Model
283) at the Core Facility of The Scripps Research Institute. The co-
localization coefficient was analyzed by National Institutes of Health
(NIH) image analysis software packages, Image J (v. 1.33).
Flow Cytometry Analysis
CHO/CD14 and CHO/TLR3 cells were stained for 1 hr with anti-CD14
and anti-TLR3, respectively. As a negative control, each relevant
control IgG was used. For intracellular staining, cells were fixed
and permeabilized with a Cytofix/Cytoperm kit according to the
manufacturer’s instructions (BD Bioscience PharMingen) before
staining with antibodies. After primary antibody staining, cells
were washed with PBS and stained with FITC-labeled secondary an-
tibodies for 1 hr. The cells were washed and resuspended in PBS
and analyzed by FACScan flow cytometry (Becton Dickinson).
Immunoprecipitation and Western Blotting
HEK293 cells (5 3 105) were transiently transfected with TLR3 and
CD14 plasmids (0.5 mg/ml each). Forty-eight hours after transfection,
cells were lysed with lysis buffer (150 mM NaCl, 1% Nonidet P40,
5 mM EDTA, 50 mM Tris-HCl, pH 7.5) containing protease inhibitor
cocktails (Roche). The supernatants were incubated with anti-Myc
antibody for 2 hr at 4ºC. Protein A-agarose beads were then added
to the mixtures and further incubated for 6 hr at 4ºC. The mixtures
were washed five times with lysis buffer, separated on a 4%–12%
Bis-Tris NuPAGE gel (Invitrogen), and transferred to nitrocellulose
membrane. Western blotting was performed by probing the mem-
brane with either anti-Myc or anti-TLR3 antibodies according to
standard protocols.
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